Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 111 of the 115 references it cites were found in a registry or an index; 32 of the 97 sources its claims cite were checked for support.

A Systematic Review of Time and Resource Use Costs of Subcutaneous Versus Intravenous Administration of Oncology Biologics in a Hospital Setting

Open access

Abstract

The introduction of human epidermal growth factor receptor 2 (HER2)-targeted treatment options, including dual HER2 blockade, has improved the prognosis for patients with HER2-positive breast cancer (BC) substantially. However, most of these treatments are administered via the intravenous (IV) route, which can present many challenges, such as long infusion and observation times, issues associated with repeated IV access, and increased strain on time and resources of medical centers and healthcare professionals. A fixed-dose combination of pertuzumab and trastuzumab for subcutaneous (SC) injection (pertuzumab, trastuzumab, and hyaluronidase-zzxf (PHESGO ® , F. Hoffmann-La Roche Ltd, Basel, Switzerland; PH FDC SC)) has been approved for use alongside chemotherapy for early-stage and metastatic HER2-positive BC. This systematic literature review was performed to identify evidence relating to time/resource use and resulting cost differences between SC and IV administration of oncology biologics in a hospital setting, and, ultimately, to inform economic modeling and associated health technology assessment of PH FDC SC. Electronic databases (Embase, MEDLINE, and EconLit) were searched on 9 April 2020. Additional hand searches were performed to identify publications not captured in the electronic database search. Publication screening and data extraction (study characteristics, participants, interventions, costs, and time/resource use) were carried out per the standard Cochrane review methodology. The quality of economic evidence of cost analyses was assessed using the 36-item checklist of the National Institute for Health and Care Excellence Single Technology Appraisal Specification for submission of evidence (January 2015). The database search identified 2,740 records, of which 237 underwent full text screening. Full text screening, prioritization of publications about patients with a cancer diagnosis, and the addition of four citations identified during the hand search resulted in 72 final included publications, relating to 71 unique studies. This included 40 publications that described the time/resource use and/or costs associated with SC versus IV trastuzumab administration for the treatment of HER2-positive BC, and 28 publications that described time/resource use and/or costs associated with rituximab SC versus IV administration for the treatment of non-Hodgkin’s lymphoma/follicular lymphoma and diffuse large B-cell lymphoma. The majority of publications showed substantial time savings for preparation and administration of SC versus IV therapy, and cost savings associated with reductions in healthcare professional time and resource use for SC administration. There was a lack of consensus between publications regarding time and cost measurements. In addition, the search was limited to publications related to anticancer drugs; the majority of the studies included were performed in European countries. This review indicated a substantial body of evidence showing time/resource and cost savings of SC versus IV administration of oncology biologics in a hospital setting, which can be used to inform economic evaluations of PH FDC SC.

Overview

CoChat Summary

TL;DR

This systematic review found that subcutaneous (SC) administration of oncology biologics in hospital settings is generally associated with substantial time/resource and cost savings versus intravenous (IV) administration. The evidence was intended to inform economic modeling and health technology assessment of the fixed-dose combination of pertuzumab and trastuzumab for SC injection (PH FDC SC).

Key findings

  • The search identified 2,740 records; after full-text screening and hand searching, 72 publications relating to 71 unique studies were included, comprising 40 publications on SC versus IV trastuzumab in HER2-positive breast cancer and 28 on SC versus IV rituximab in NHL/FL or DLBCL.
  • Most publications showed substantial time savings for SC versus IV therapy: trastuzumab preparation required 14–21 min IV versus 0–11 min SC; administration was 90/30 min IV for loading/subsequent doses versus 5–10 min SC; active HCP time was 13–92 min IV versus 7–30 min SC; and chair time was 47–180 min IV versus 8–120 min SC.
  • Cost savings with SC versus IV trastuzumab were reported in all but one cost publication; in seven publications, direct costs for SC were approximately 1.3–6% lower, with one Russian study reporting a 12.6% decrease and one UK study reporting a 2.8-fold decrease.
  • For rituximab, chair/infusion time was considerably shorter with SC versus IV in all reporting publications, ranging from 150–262 min IV (one study reported 372 min) to 6–11 min SC, with time saved ranging from 1 h 45 min to 3 h 26 min.

Methods

  • Systematic literature review searched Embase, MEDLINE, and EconLit via Ovid on 9 April 2020, with additional hand searches; screening and data extraction followed standard Cochrane review methodology with double independent screening and verification.
  • Eligibility included studies comparing IV- versus SC-administered interventions and reporting costs or time/resource use; after broad screening, the review was restricted to anticancer drugs, prioritizing patients with a cancer diagnosis.
  • Quality of economic evidence in cost analyses was assessed using the 36-item National Institute for Health and Care Excellence Single Technology Appraisal checklist, adapted from Drummond and Jefferson; time/resource and cost limitations were assessed using an adapted Drummond/Molinier approach.

Limitations

  • Stated in the paper: there was a lack of consensus between publications regarding time and cost measurements; the search was limited to publications related to anticancer drugs; and the majority of included studies were performed in European countries.
  • Stated in the paper: drug costs of the treatments administered were not considered, and the focus was on hospital administration only.
  • Evident from the text: many included publications were congress abstracts with limited detail, study designs and reporting of data collection/analysis were inconsistent, and the wide range of study designs and paucity of studies reporting individual outcomes prevented categorizing studies by risk.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s41669-022-00361-3

Cites

111 of 111 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 PRISMA diagram: Study flow of included and excluded publications. PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses
Fig. 1 PRISMA diagram: Study flow of included and excluded publications. PRISMA Preferred Reporting Items for Systematic Reviews and Meta-AnalysesCC BY-NC · PubMed Central
Fig. 2 Numbers of publications reporting time/resource use and costs for each agent/indication
Fig. 2 Numbers of publications reporting time/resource use and costs for each agent/indicationCC BY-NC · PubMed Central
Fig. 3 HCP time as reported across included studies. HCP healthcare professional, IV intravenous, mins min, SC subcutaneous. Δ, difference in HCP time between IV and SC administration presented in min and as a percentage of total time
Fig. 3 HCP time as reported across included studies. HCP healthcare professional, IV intravenous, mins min, SC subcutaneous. Δ, difference in HCP time between IV and SC administration presented in min and as a percentage of total timeCC BY-NC · PubMed Central
Fig. 4 Patient chair time reported across included studies. IV intravenous, mins min, SC subcutaneous. Δ, difference in chair time between IV and SC administration presented in min and as a percentage of total time
Fig. 4 Patient chair time reported across included studies. IV intravenous, mins min, SC subcutaneous. Δ, difference in chair time between IV and SC administration presented in min and as a percentage of total timeCC BY-NC · PubMed Central
Fig. 5 Differences in chair time for IV and SC administration for countries included in the PrefHer time-and-motion study. HHS hand-held syringe, IV intravenous, SC subcutaneous, SID single-use injection device. Source: De Cock et al 2016 [25]
Fig. 5 Differences in chair time for IV and SC administration for countries included in the PrefHer time-and-motion study. HHS hand-held syringe, IV intravenous, SC subcutaneous, SID single-use injection device. Source: De Cock et al 2016 [25]CC BY-NC · PubMed Central

Verification

Claims the paper makes

14 Valid · 1 Not valid · 27 Not checked · 52 Own results and interpretations

40 more claims · 7 with their cited sources checked

Create a free account to see all 94 claims and to verify the 65 references still open.

See all claims — free account
  • It may state two separate claims as one. 34
  • Probably not a substantial claim. 23

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 5

Citations

Cites

Show all 115 references

Research works printed but not linked: 6

  1. De Cock E, Semiglazov V, Lopez-Vivanco G, Verma S, Pivot X, Gligorov J, et al. Time savings with trastuzumab subcutaneous vs. intravenous administration: a time and motion study. In: Poster presentation at the 13th St Gallen International Breast Cancer Conference; 13–16 March 2013. Abstract XXX; St Gallen.
  2. De La Vega ZI, Celia A, Manuel P, Agustín S, Miguel C. Economic impact of the introduction of subcutaneous trastuzumab in the pharmacotherapeutic guide. Eur J Clin Pharm. 2017;19(3):213–5.
  3. Di Rocco A, Scerbo G, Ansuinelli M, al e. Efficacy, safety and cost analysis of subcutaneous vs intravenous rituximab in patients with diffuse large b-cell lymphoma treated with RCHOP. Haematologica. 2017;102:108.
  4. Irwin S, Rowntree C, Cosh H, Bloodworth C. Positive benefits of changing from intravenous rituximab administration to subcutaneous administration: a single centre experience. British Journal of Haematology. 2017;176:Abstract E1151.
  5. Annibali O, Tomarchio V, Becilli M. Management, economic and social impact of sub-cutaneous rituximab administration in diffuse large b cell lymphoma (DLBCL) and follicular lymphoma. Haematologica. 2017;102:111.
  6. Anderson KC, Landgren O, Arend RC, Chou J, Jacobs IA. Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics. Fut Oncol. 2019;15(28):3267–81. · DOI · Paper page

Cited by

See all 66

Metadata

Authors
McCloskey, C., Ortega, M. T., Nair, S., Garcia, M. J., & Manevy, F.
Affiliations
F. Hoffmann-La Roche AG (CH)
Corresponding author
Garcia, Maria João
Venue
PharmacoEconomics - Open
Published
2022-08-23
Volume
7
Issue
1
Pages
3-36
ISSN
  • 2509-4254 (ISSN-L)
  • 2509-4262
OpenAlex
W4293253058
Cited by
66
References
115
Citations by year
2026: 19 · 2025: 25 · 2024: 15 · 2023: 7
FWCI
2.17
Type
journal article
Language
en
Open access
Licence
Locations
  • PharmacoEconomics - Open (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
Funders
F. Hoffmann-La Roche Ltd.
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords
subcutaneous administration, intravenous administration, HER2-positive breast cancer, trastuzumab, pertuzumab, rituximab, non-Hodgkin lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, health care costs, hospital costs, health technology assessment, economic modeling, infusion duration, hyaluronidase

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Systematic Review of Time and Resource Use Costs of Subcutaneous Versus Intravenous Administration of Oncology Biologics in a Hospital Setting. https://app.cochat.ai/papers/10.1007/s41669-022-00361-3
The paper
McCloskey, C., Ortega, M. T., Nair, S., Garcia, M. J., & Manevy, F. (2023). A Systematic Review of Time and Resource Use Costs of Subcutaneous Versus Intravenous Administration of Oncology Biologics in a Hospital Setting. PharmacoEconomics - Open. https://doi.org/10.1007/s41669-022-00361-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.